Compare SOLS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | GKOS |
|---|---|---|
| Founded | 2025 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.7B |
| IPO Year | 2025 | 2015 |
| Metric | SOLS | GKOS |
|---|---|---|
| Price | $60.15 | $165.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $78.60 | ★ $199.31 |
| AVG Volume (30 Days) | ★ 1.9M | 927.3K |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $3,886,000,000.00 | $507,442,000.00 |
| Revenue This Year | $7.28 | $36.30 |
| Revenue Next Year | $5.75 | $23.25 |
| P/E Ratio | $46.75 | ★ N/A |
| Revenue Growth | 3.08 | ★ 32.33 |
| 52 Week Low | $40.43 | $73.16 |
| 52 Week High | $90.80 | $191.62 |
| Indicator | SOLS | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 50.94 |
| Support Level | $55.24 | $147.72 |
| Resistance Level | $63.65 | $186.99 |
| Average True Range (ATR) | 1.89 | 7.22 |
| MACD | 0.29 | 0.94 |
| Stochastic Oscillator | 76.58 | 72.38 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.